Chen Hui-Min, Zhang Ding-Guo, Wu Jin-Xia, Pei Dong-Sheng, Zheng Jun-Nian
Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, China E-mail :
Asian Pac J Cancer Prev. 2014;15(5):2313-8. doi: 10.7314/apjcp.2014.15.5.2313.
Peroxisome proliferator-activated receptor gamma (PPAR-γ), a ligand-dependent nuclear transcription factor, has been found to widely exist in tumor tissues and plays an important role in affecting tumor cell growth. In this study, we investigated the effect of PPAR-γ on aspects of the cervical cancer malignant phenotype, such as cell proliferation and apoptosis. Cell growth assay, Western blotting, Annexin V and flow cytometry analysis consistently showed that treatment with troglitazone (TGZ, a PPAR-γ agonist) led to dose-dependent inhibition of cervical cancer cell growth through apoptosis, whereas T0070907 (another PPAR-γ antagonist???) had no effect on Hela cell proliferation and apoptosis. Furthermore, we also detected the protein expression of p53, p21 and Mdm2 to explain the underlying mechanism of PPAR-γ on cellular apoptosis. Our work, finally, demonstrated the existence of the TGZ-PPAR-γ-p53 signaling pathway to be a critical regulator of cell apoptosis. These results suggested that PPAR-γ may be a potential therapeutic target for cervical cancer.
过氧化物酶体增殖物激活受体γ(PPAR-γ)是一种依赖配体的核转录因子,已发现其广泛存在于肿瘤组织中,并在影响肿瘤细胞生长方面发挥重要作用。在本研究中,我们调查了PPAR-γ对宫颈癌恶性表型各方面的影响,如细胞增殖和凋亡。细胞生长测定、蛋白质印迹法、膜联蛋白V和流式细胞术分析一致表明,用曲格列酮(TGZ,一种PPAR-γ激动剂)处理可通过凋亡导致宫颈癌细胞生长的剂量依赖性抑制,而T0070907(另一种PPAR-γ拮抗剂)对Hela细胞增殖和凋亡没有影响。此外,我们还检测了p53、p21和Mdm2的蛋白质表达,以解释PPAR-γ对细胞凋亡的潜在机制。我们的研究最终证明,TGZ-PPAR-γ-p53信号通路的存在是细胞凋亡的关键调节因子。这些结果表明,PPAR-γ可能是宫颈癌的一个潜在治疗靶点。